Skip to main content
Caplight Logo









Vivet Therapeutics

Vivet Therapeutics

Private
ParisHealthcare & Life Scienceshttps://www.vivet-therapeutics.com/

Last Round

Grant

Feb 1, 2024

Est. Valuation

$340M

Total Funding Raised

$97.36M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Vivet Therapeutics is a biotechnology company that develops novel gene therapy treatments for rare, inherited metabolic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

gene therapyadeno-associated virusAAVWilson diseaseinherited metabolic diseaseliver-directed therapybiotechclinical-stage biotechrare diseaseorphan druggene replacementbiopharmaceuticaltranslational medicineATP7B geneclinical trial

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vivet Therapeutics Comparables

Compare Vivet Therapeutics with similar companies based on industry and business-model similarity.

Vivet Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ultragenyx Pharmaceutical Inc.
83%
Genespire
78%
GEMMA Biotherapeutics
75%

Vivet Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 1, 2024
StrategicMar 20, 2019
Series AMay 4, 2017

Key People

Founding team and executive leadership

Jean-Philippe Combal

Co-Founder Chief Executive Officer

Founding Team

Vivet Therapeutics Investors

Notable investors and investment history

Vivet Therapeutics investors
InvestorRounds
Roche Venture FundSeries A
Idinvest PartnersSeries A
Ysios CapitalSeries A
CVJStrategic
HealthCapSeries A
Roche Venture FundSeries A
PfizerStrategic

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Monthly visitors increased 32% MoM to 5.9K.

  • Apr 22, 2026

    Monthly visitors increased 61% MoM.

Vivet Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vivet Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vivet Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis
Employee Range18
Year Founded2016
Last FundingFeb 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?